X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Under the agreement, Astellas will have access to Invenra’s cutting-edge B-Body® bispecific antibody platform to support its focused research and development initiatives.
Lead Product(s): Undisclosed
Therapeutic Area: Technology Product Name: Undisclosed
Highest Development Status: Discovery PlatformProduct Type: Large molecule
Recipient: Invenra
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement April 09, 2024
Details:
The collaboration is to Utilize CytomX’s Novel Probody® Technology Platform for CD3 Bispecific Targets for the treatment of cancer. CytomX and Astellas are also collaborating on additional conditionally activated TCB programs.
Lead Product(s): Undisclosed
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Large molecule
Recipient: CytomX Therapeutics
Deal Size: $1,680.0 million Upfront Cash: $80.0 million
Deal Type: Collaboration April 03, 2024
Details:
Padcev (enfortumab vedotin-ejfv), a nectin-4 inhibitor ADC in combination with Keytruda (pembrolizumab), a PD-1 inhibitor. It is being evaluated for the treatment of locally advanced or metastatic urothelial cancer.
Lead Product(s): Enfortumab Vedotin,Pembrolizumab
Therapeutic Area: Oncology Product Name: Padcev
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Pfizer Inc
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 28, 2024
Details:
Astellas' Vyloy (zolbetuximab), a CLDN 18.2 inhibitor has been approved in combination with chemotherapy for patients with HER2-negative, CLDN18.2 positive, unresectable, advanced or recurrent gastric cancer.
Lead Product(s): Zolbetuximab,Oxaliplatin,Calcium Folinate
Therapeutic Area: Oncology Product Name: VYLOY
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 26, 2024
Details:
Xtandi (enzalutamide) becomes the first and only androgen receptor signaling inhibitor approved by the FDA for the treatment of patients with nonmetastatic castration-sensitive prostate cancer with high-risk BCR for metastasis.
Lead Product(s): Enzalutamide
Therapeutic Area: Oncology Product Name: Xtandi
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Pfizer Inc
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 22, 2024
Details:
The clinical candidate is the first PROBODY® T-cell engaging bispecific (TCB) molecule under the alliance between CytomX and Astellas to progress into a GLP toxicology study.
Lead Product(s): Undisclosed
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Large molecule
Recipient: CytomX Therapeutics
Deal Size: $1,680.0 million Upfront Cash: $80.0 million
Deal Type: Collaboration March 18, 2024
Details:
Under the terms of the agreement, Ubiquigent will provide Nanna with access to its deubiquitylase (DUB) focused drug discovery platform to support the development of novel therapeutics for human disease targets selected by Nanna.
Lead Product(s): Undisclosed
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: DiscoveryProduct Type: Small molecule
Recipient: Ubiquigent
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement March 11, 2024
Details:
Cresemba (isavuconazonium sulfate) is the prodrug of isavuconazole which is an azole antifungal indicated for the treatment of invasive aspergillosis and invasive mucormycosis.
Lead Product(s): Isavuconazonium Sulfate
Therapeutic Area: Infections and Infectious Diseases Product Name: Cresemba
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 11, 2024
Details:
Veozah (fezolinetant) is a neurokinin 3 (NK3) receptor antagonist indicated for the treatment of moderate to severe vasomotor symptoms due to menopause.
Lead Product(s): Fezolinetant
Therapeutic Area: Obstetrics/Gynecology (Women’s Health) Product Name: Veozah
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 03, 2024
Details:
Padcev (enfortumab vedotin-ejfv), a nectin-4 inhibitor ADC in combination with Keytruda (pembrolizumab), a PD-1 inhibitor. It is being evaluated for the treatment of locally advanced or metastatic urothelial cancer.
Lead Product(s): Enfortumab Vedotin,Pembrolizumab
Therapeutic Area: Oncology Product Name: Padcev
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Merck & Co
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 15, 2024
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
